|
Canada-0-Social Service Welfare Organ ไดเรกทอรีที่ บริษัท
|
ข่าว บริษัท :
- Hemophilia: What to know about your treatment options
Dr Sridharan recommends working with a hemophilia treatment center to guide treatment and care You can find and contact regional hemophilia treatment centers through the CDC’s online directory Understanding your treatment options There are three main types of hemophilia treatment: factor replacement, non-factor replacement and gene therapy
- List of 43 Hemophilia A Medications Compared - Drugs. com
Expanded Access is a potential pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available
- Hemophilia Therapies - Rare Disease Advisor
Koāte ® (antihemophilic factor [human]), also known as Koāte-DVI, is a human plasma-derived FVIII indicated for the treatment and prevention of bleeding episodes in patients with hemophilia A Initially approved in the US in 1974, the processing methods have been updated over the years to make the product safer from viral contamination
- AHF (Antihemophilic Factor): Uses Side Effects - Cleveland Clinic
AHF (antihemophilic factor) is a medication that prevents or manages bleeding if you have hemophilia A This condition keeps your blood from clotting as it should so you bleed more than expected A healthcare provider will usually give you this injection in a hospital or clinic setting
- List of Treatments for Hemophilia | MyHemophiliaTeam
Jivi (Antihemophilic Factor [Recombinant] Pegylated-Aucl) Overview Jivi is a recombinant antihemophilic factor approved by the U S Food and Drug Administration (FDA) for the treatment and management of hemophilia A (congenital factor VIII [8] deficiency) in previously treated… read more
- Approved Treatments for Hemophilia – Hemophilia News Today
The primary treatment for hemophilia is replacement therapy that supplies the clotting factors to hemophilia patients who lack them Other approved treatments include bypassing agents, gene therapies, and nonfactor replacement therapies Alphanate (human antihemophilic factor von Willebrand factor complex) is a factor replacement therapy to
- Know Your Treatment Options | Novoeight® (Antihemophilic Factor . . .
When comparing your hemophilia A treatment choices, you might also consider extended half-life (EHL) Esperoct ® [antihemophilic factor (recombinant), glycopegylated-exei] We start with the existing Novoeight ® molecule and add PEGylation technology to extend the factor’s half-life
- Acquired Hemophilia Treatment Management - Medscape
Recombinant antihemophilic factor, porcine sequence Historically, porcine factor VIII has provided a good effect A porcine sequence recombinant FVIII (rpFVIII; Obizur) was approved by the US Food and Drug Administration (FDA) in 2014 for treatment of bleeding episodes in adults with acquired hemophilia
- Understanding Current Bleeding Disorder Treatments | NBDF
Non-factor replacement therapies: These products help prevent bleeding or assist in better clotting using other methods in the body besides factor replacement therapy Non-factor replacement therapies include: Emicizumab (Hemlibra) is a therapy used to treat hemophilia A, to prevent bleeding episodes in people both with and without inhibitors It is known as a factor VIII(8) mimetic because it
|
|